BCL2 associated agonist of cell death (BAD)

BCL2 associated agonist of cell death (**BAD**) is a pro-apoptotic member of the BH3-only subfamily within the larger Bcl‑2 family. It promotes programmed cell death by binding anti-apoptotic proteins such as **BCL‑xL**, **Bcl‑W**, and **Bcl‑2**, neutralizing their function and enabling mitochondrial outer membrane permeabilization—a key step leading to caspase activation and apoptosis. The function of BAD is tightly regulated through post-translational modifications; notably, **phosphorylation at specific serine residues inhibits its pro-apoptotic action by causing it to bind 14–3–3 proteins in the cytoplasm rather than associating with mitochondria-bound targets. Dephosphorylated BAD localizes to mitochondria where it exerts its apoptogenic effect.[1][4][6]}**\n\nDysregulation or altered expression/phosphorylation status has been implicated in various cancers—where increased survival signaling leads to persistent inhibition—and neurodegenerative conditions—where excessive dephosphorylation may contribute to inappropriate neuronal loss.[10]\n\n---\n\n#### Note on Query Correction:\nThe term "Bad phosphorylation" refers specifically to a regulatory modification state rather than an independent molecular entity or drug target. For structured data purposes, use "BCL2 associated agonist of cell death" (BAD) as canonical name/target entry; treat "Bad phosphorylation" only as functional context describing regulation/modification state.[1][6]

Other names

BADBcl-2-associated death promoterBcl2-Binding component 6

Drugs that inhibit kinases such as Akt can prevent phosphorylation of BAD, thereby promoting its pro-apoptotic activity. Conversely, agents that increase survival kinase activity promote BAD phosphorylation and cytoplasmic sequestration by 14‑3‑3 proteins, reducing apoptosis.\n\nDrugs directly targeting anti-apoptotic proteins in the same pathway (e.g., venetoclax for BCL2) act by freeing up pro-apoptotic factors like dephosphorylated BAD.